European Neuropsychopharmacology
Volume 20, Issue 12 , Pages 866-874 , December 2010

Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis: A study in healthy volunteers

  • G.E. Jacobs

      Affiliations

    • Centre for Human Drug Research, Leiden, The Netherlands
    • Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands
    • Corresponding Author InformationCorresponding author. Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden, The Netherlands. Tel.: +31 71 524 6497; fax: +31 71 524 6499.
    • ,
  • E.G.J. Hulskotte

      Affiliations

    • NV Organon, Part of Schering-Plough Corporation, Department of Clinical Pharmacology and Kinetics, Oss, The Netherlands
    • ,
  • M.L. de Kam

      Affiliations

    • Centre for Human Drug Research, Leiden, The Netherlands
    • ,
  • G. Zha

      Affiliations

    • Clinical Research Center Laboratory, Peking Union Medical College Hospital, Beijing, China
    • ,
  • J. Jiang

      Affiliations

    • Clinical Research Center Laboratory, Peking Union Medical College Hospital, Beijing, China
    • ,
  • P. Hu

      Affiliations

    • Clinical Research Center Laboratory, Peking Union Medical College Hospital, Beijing, China
    • ,
  • Q. Zhao

      Affiliations

    • Clinical Research Center Laboratory, Peking Union Medical College Hospital, Beijing, China
    • ,
  • J. van Pelt

      Affiliations

    • Department of Clinical Chemistry, Leiden University Medical Centre, Leiden, The Netherlands
    • ,
  • J.G. Goekoop

      Affiliations

    • Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands
    • Rivierduinen Mental Health Care Organisation, Oegstgeest, The Netherlands
    • ,
  • F.G. Zitman

      Affiliations

    • Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands
    • ,
  • J.M.A. van Gerven

      Affiliations

    • Centre for Human Drug Research, Leiden, The Netherlands

Received 6 January 2010 ,Revised 2 June 2010 ,Accepted 17 June 2010.

References 

  1. Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: implications for stress adaptation. Regul. Pept. 2000;96:23–29
  2. Chiodera P, Volpi R, Delsignore R, Marchesi C, Salati G, Camellini L, et al. Different effects of metoclopramide and domperidone on arginine-vasopressin secretion in man. Br. J. Clin. Pharmacol. 1986;22:479–482
  3. Coiro V, Capretti L, Speroni G, Volpi R, Fagnoni F, Bianconi L, et al. Muscarinic cholinergic, but not serotoninergic mediation of arginine vasopressin response to metoclopramide in man. Clin. Endocrinol. 1989;31:491–498Oxf
  4. DeBold CR, Sheldon WR, DeCherney GS, Jackson RV, Alexander AN, Vale W, et al. Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. J. Clin. Invest. 1984;73:533–538
  5. Dempster EL, Burcescu I, Wigg K, Kiss E, Baji I, Gadoros J, et al. Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch. Gen. Psychiatry. 2007;64:1189–1195
  6. Dinan TG, Scott LV. Anatomy of melancholia: focus on hypothalamic–pituitary–adrenal axis overactivity and the role of vasopressin. J. Anat. 2005;207:259–264
  7. Dinan TG, Lavelle E, Scott LV, Newell-Price J, Medbak S, Grossman AB. Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: evidence of enhanced vasopressinergic responsivity. J. Clin. Endocrinol. Metab. 1999;84:2238–2240
  8. Dinan TG, O'Brien S, Lavelle E, Scott LV. Further neuroendocrine evidence of enhanced vasopressin V3 receptor responses in melancholic depression. Psychol. Med. 2004;34:169–172
  9. Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the hypothalamic–pituitary–adrenal axis under stress: an old concept revisited. Front. Neuroendocrinol. 2004;25:132–149
  10. Favrod-Coune C, Raux-Demay MC, Proeschel MF, Bertagna X, Girard F, Luton JP. Potentiation of the classic ovine corticotrophin releasing hormone stimulation test by the combined administration of small doses of lysine vasopressin. Clin. Endocrinol. 1993;38:405–410Oxf
  11. Follenius M, Brandenberger G, Hietter B. Diurnal cortisol peaks and their relationships to meals. J. Clin. Endocrinol. Metab. 1982;55:757–761
  12. Gartside SE, Cowen PJ. Mediation of ACTH and prolactin responses to 5-HTP by 5-HT2 receptors. Eur. J. Pharmacol. 1990;179:103–109
  13. Gijsman HJ, van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J. Clin. Psychopharmacol. 1998;18:289–295
  14. Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, et al. Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J. Clin. Psychopharmacol. 2002;22:183–189
  15. Goekoop JG, Wiegant VM. Support for two subcategories of depression with different vasopressinergic mechanisms in the field of melanhcolia. Curr. Psychiatry Rev. 2009;5:127–136
  16. Holsboer F. The dexamethasone suppression test in depressed patients: clinical and biochemical aspects. J. Steroid Biochem. 1983;19:251–257
  17. Holsboer F, Gerken A, Steiger A, Benkert O, Muller OA, Stalla GK. Corticotropin-releasing-factor induced pituitary–adrenal response in depression. Lancet. 1984;1:55
  18. Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Muller OA. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J. Med. 1984;311:1127
  19. Jacobs GE, Kamerling IM, de Kam ML, Derijk RH, van Pelt J, Zitman FG, et al. Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron. J. Psychopharmacol. 2010;24(1):65–72(Epub, 2008 Aug 21)
  20. Jacobs GE, Hulskotte EG, van Gerven JM, Zuurman L, de Kam ML, Elassaiss-Schaap J, et al. Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary- adrenal axis modulation: neuroendocrine, cardiovascular and coagulatory effects. J. Psychopharmacol. 2010;(Mar 23, Electronic publication ahead of print)
  21. Jacobs GE, van Gerven JM, de Kam ML, Schaap J, Ruigt G, van Pelt J, et al. A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus-pituitary-adrenal axis more integrally in healthy volunteers. J. Psychopharmacol. 2010;(Apr 1, Electronic publication ahead of print)
  22. Jorgensen H, Knigge U, Kjaer A, Moller M, Warberg J. Serotonergic stimulation of corticotropin-releasing hormone and pro-opiomelanocortin gene expression. J. Neuroendocrinol. 2002;14:788–795
  23. Lamberts SW, Verleun T, Oosterom R, de JF, Hackeng WH. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. J. Clin. Endocrinol. Metab. 1984;58:298–303
  24. Nomura K, Kurimoto F, Demura H, Sakurai H, Nomura T, Zibiki K, et al. Effect of metoclopramide in plasma vasopressin in man. Clin. Endocrinol. 1984;21:117–121Oxf
  25. Pitzel L, Konig A. Lack of response in the release of oxytocin and vasopressin from isolated neurohypophyses to dopamine, met-enkephalin and leu-enkephalin. Exp. Brain Res. 1984;56:221–226
  26. Quigley ME, Yen SS. A mid-day surge in cortisol levels. J. Clin. Endocrinol. Metab. 1979;49:945–947
  27. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Des. 2005;11:205–225
  28. Scott LV, Dinan TG. Vasopressin and the regulation of hypothalamic–pituitary–adrenal axis function: implications for the pathophysiology of depression. Life Sci. 1998;62:1985–1998
  29. Scott LV, Dinan TG. Vasopressin as a target for antidepressant development: an assessment of the available evidence. J. Affect. Disord. 2002;72:113–124
  30. Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary–adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol. Psychiatry. 1999;45:1447–1454
  31. Seki K, Kato T, Sekiya S. Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea. Clin. Endocrinol. 1997;46:203–207Oxf
  32. Smarius LJ, Jacobs GE, Hoeberechts-Lefrandt DH, de Kam ML, van der Post JP, de Rijk R, et al. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. J. Psychopharmacol. 2008;22:426–433
  33. Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress. 2004;7:75–83
  34. von Bardeleben U, Holsboer F. Human corticotropin releasing hormone: clinical studies in patients with affective disorders, alcoholism, panic disorder and in normal controls. Prog. Neuropsychopharmacol. Biol. Psychiatry. 1988;12(Suppl):S165–S187
  35. Walsh P, Spelman L, Sharifi N, Thakore JH. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology. 2005;30:431–437

PII: S0924-977X(10)00136-7

doi: 10.1016/j.euroneuro.2010.06.009

European Neuropsychopharmacology
Volume 20, Issue 12 , Pages 866-874 , December 2010

Article Tools

* Image Usage & Resolution